Dr. Ramalingam on Side Effects Associated With Immunotherapy in Lung Cancer

Name: Dr. Ramalingam on Side Effects Associated With Immunotherapy in Lung Cancer
Uploaded: 2015-08-03T13:54:00.000Z
Description: Suresh S. Ramalingam, MD, discusses important considerations for patients, caregivers, nurses and physicians when treatment with an immunotherapy begins.

August 3, 2015

Suresh S. Ramalingam, MD

Article

Suresh S. Ramalingam, MD, discusses important considerations for patients, caregivers, nurses and physicians when treatment with an immunotherapy begins.

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses important considerations for patients, caregivers, nurses and physicians when treatment with an immunotherapy begins.

Related Content

Experts Make the Case for More Inclusive Lung Cancer Screening Guidelines

December 6th 2023

Article

A smoking-duration cutoff may be a better measure for determining lung cancer screening eligibility compared with smoking pack-years.

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023

Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Should You Wait for NGS Results Before Initiating NSCLC Treatment?

November 17th 2023

Article

Beth Sandy, MSN, CRNP, and Tajuana Bradley, MSN, APRN-BC, discuss the importance of molecular testing in non–small cell lung cancer.

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Early ctDNA Monitoring May Help Optimize Outcomes in NSCLC

November 13th 2023

Article

Leveraging circulating tumor (ct)DNA may help expedite the time to treatment and enhance survival prospects for individuals with lung cancer.

Trilaciclib Snags ASCO Recommendation in Extensive-Stage Small Cell Lung Cancer

November 11th 2023

Article

New ASCO guidelines recommend trilaciclib for patients with untreated or previously treated extensive-stage small cell lung cancer who are receiving chemotherapy or chemoimmunotherapy.

Related Content

Experts Make the Case for More Inclusive Lung Cancer Screening Guidelines

December 6th 2023

Article

A smoking-duration cutoff may be a better measure for determining lung cancer screening eligibility compared with smoking pack-years.

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023

Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Should You Wait for NGS Results Before Initiating NSCLC Treatment?

November 17th 2023

Article

Beth Sandy, MSN, CRNP, and Tajuana Bradley, MSN, APRN-BC, discuss the importance of molecular testing in non–small cell lung cancer.

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Early ctDNA Monitoring May Help Optimize Outcomes in NSCLC

November 13th 2023

Article

Leveraging circulating tumor (ct)DNA may help expedite the time to treatment and enhance survival prospects for individuals with lung cancer.

Trilaciclib Snags ASCO Recommendation in Extensive-Stage Small Cell Lung Cancer

November 11th 2023

Article

New ASCO guidelines recommend trilaciclib for patients with untreated or previously treated extensive-stage small cell lung cancer who are receiving chemotherapy or chemoimmunotherapy.